Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 23211837)

1.

Ipilimumab activity in advanced uveal melanoma.

Khattak MA, Fisher R, Hughes P, Gore M, Larkin J.

Melanoma Res. 2013 Feb;23(1):79-81. doi: 10.1097/CMR.0b013e32835b554f.

PMID:
23211837
2.

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M.

Cancer Immunol Immunother. 2012 Jan;61(1):41-8. doi: 10.1007/s00262-011-1089-0. Epub 2011 Aug 11.

PMID:
21833591
3.

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.

Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA.

Ann Oncol. 2013 Nov;24(11):2911-5. doi: 10.1093/annonc/mdt376. Epub 2013 Sep 25.

4.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.

Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2.

5.

Ipilimumab in melanoma.

Specenier P.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1511-21. doi: 10.1586/era.12.132. Epub 2012 Nov 26.

PMID:
23181437
6.

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.

Alexander M, Mellor JD, McArthur G, Kee D.

Med J Aust. 2014 Jul 7;201(1):49-53.

PMID:
24999899
7.

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M.

J Exp Clin Cancer Res. 2013 Oct 25;32:82. doi: 10.1186/1756-9966-32-82.

8.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
9.

Uveal melanoma.

Spagnolo F, Caltabiano G, Queirolo P.

Cancer Treat Rev. 2012 Aug;38(5):549-53. doi: 10.1016/j.ctrv.2012.01.002. Epub 2012 Jan 24. Review.

PMID:
22270078
10.

A pilot study of sunitinib malate in patients with metastatic uveal melanoma.

Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T.

Melanoma Res. 2012 Dec;22(6):440-6. doi: 10.1097/CMR.0b013e328358b373.

PMID:
23114504
11.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU.

Cancer Immunol Immunother. 2014 May;63(5):449-58. doi: 10.1007/s00262-014-1528-9. Epub 2014 Mar 8.

PMID:
24609989
12.

Ipilimumab in advanced melanoma: reports of long-lasting responses.

Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R.

Melanoma Res. 2012 Jun;22(3):263-70. doi: 10.1097/CMR.0b013e328353e65c.

PMID:
22516968
13.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
14.

Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.

Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, Kuppen PJ, van de Velde CJ, Tollenaar RA.

Melanoma Res. 2004 Feb;14(1):67-72.

PMID:
15091197
15.

Uveal melanoma: natural history and treatment options for metastatic disease.

Wöll E, Bedikian A, Legha SS.

Melanoma Res. 1999 Dec;9(6):575-81. Review.

PMID:
10661768
16.

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.

Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P.

J Exp Clin Cancer Res. 2014 Apr 4;33:30. doi: 10.1186/1756-9966-33-30.

17.

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2011 Apr;60(4):467-77. doi: 10.1007/s00262-010-0958-2. Epub 2010 Dec 18.

PMID:
21170646
18.

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.

Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V.

J Neurooncol. 2014 May;118(1):109-16. doi: 10.1007/s11060-014-1400-y. Epub 2014 Feb 16.

19.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.

Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M.

Eur J Cancer. 2014 Jan;50(1):121-7. doi: 10.1016/j.ejca.2013.09.007. Epub 2013 Oct 4.

PMID:
24100024
20.

Ipilimumab: a guide to its use in advanced melanoma.

Lyseng-Williamson KA, Sanford M.

Am J Clin Dermatol. 2012 Oct 1;13(5):349-54. doi: 10.2165/11209100-000000000-00000.

PMID:
22849352
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk